SEC Form 4 · accession 0001209191-17-048481
KYNTRA BIO, INC. · KYNB
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
K Peony Yu
Officer — Chief Medical Officer
Period of report
Aug 8, 2017
Accepted (ET)
Aug 10, 2017 · 7:16 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000921299
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 8, 2017 | M | 20,000 | $14.575 | A | 236,507 | D | |
| Common StockF1,F2 | Aug 8, 2017 | S | 32,400 | $50.50 | D | 204,107 | D | |
| Common StockF1,F3 | Aug 8, 2017 | S | 5,100 | $51.11 | D | 199,007 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F4 | $14.575 | Aug 8, 2017 | M | 20,000 | D | — | Mar 19, 2024 | Common Stock | 20,000 | 77,000 | D |
Explanation of responses
- F1Shares sold pursuant to a 10b5-1 plan.
- F2The shares were sold at prices ranging from $50.10 to $50.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F3The shares were sold at prices ranging from $51.00 to $51.45. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- F4Fully vested.